Journal of Ethnopharmacology, Год журнала: 2024, Номер 333, С. 118439 - 118439
Опубликована: Июнь 9, 2024
Язык: Английский
International Journal of Pharmaceutics, Год журнала: 2025, Номер unknown, С. 125566 - 125566
Опубликована: Апрель 1, 2025
Язык: Английский
Процитировано
0
Frontiers in Medicine, Год журнала: 2025, Номер 12
Опубликована: Апрель 17, 2025
Atopic dermatitis (AD) is a chronic inflammatory skin condition with high prevalence worldwide and multifaceted pathogenesis. In general, patients moderate to severe AD often experience relapse after discontinuing treatment. Therefore, understand the possible factors of look for biological markers that predict or poor prognosis will be helpful clinical Mutations in genes such as FLG, SPINK5, STAT, KIF3A, claudin-1, Ovol1, HLA-DRB1 offer new insights into genetic basis AD. Routine may help improve patient lifestyle, highlight importance environmental influences (including psychological stress), support clinicians optimizing anti-infective treatment strategies. The axis (CD30–CD30L axis, IL-9-IL-18 axis) provides pathways target future therapies. Low NKG2D expression have adverse effects on prognosis. Prognostic biomarkers can play an important role monitoring, disease progression recurrence, provide possibility more personalized
Язык: Английский
Процитировано
0
Mediators of Inflammation, Год журнала: 2025, Номер 2025(1)
Опубликована: Янв. 1, 2025
Background: Liangxue Qushi Zhiyang Decoction (LQZ) is a traditional formula known for its efficacy in treating Atopic Dermatitis (AD). However, the specific mechanisms through which LQZ alleviates AD symptoms remain largely unknown. The objective of this study to investigate protective effects on and uncover potential action. Methods: An model was established mice using 2,4‐dinitrochlorobenzene (DNCB). Mice were then orally administered or prednisolone (PDN). Throughout treatment period, dermatitis scores scratching frequencies regularly monitored. Histopathological analyses conducted hematoxylin eosin (H&E) staining toluidine blue (TB) staining. Serum levels inflammatory cytokines measured enzyme‐linked immunosorbent assay (ELISA). Further, tandem mass tag (TMT) labeling quantitative proteomics employed identify differentially expressed proteins (DEPs). Enrichment analysis pinpoint targets pathways involved LQZ’s therapeutic Finally, validation experiments performed further explore core treatment.. Results: notably mitigated skin barrier damage response induced by DNCB mice, reduced serum IgE, IL‐4, IL‐1 β . Proteomic identified 248 with differential expression, implicating multiple LQZ’ Among these, Fc gamma R(Fc γ R)−mediated phagocytosis pathway emerged as crucial factor AD’s immune responses. Key associated pathway, including Fc‐gamma RIII (Fcgr3), V‐yes‐1 Yamaguchi sarcoma viral related oncogene homolog (Lyn), Tyrosine‐protein kinase (Syk), Phosphoinositide phospholipase C‐gamma‐2 (Plcg2), Neutrophil cytosol 1 (Ncf1), Ras‐related C3 botulinum toxin substrate 2 (Rac2) Actin‐related protein 2/3 complex subunit 3 (Arpc3), exhibited significantly expression following treatment. Conclusion: effective alleviating reactions. Its anti‐AD properties may be attributed inhibition R‐mediated phagocytic pathway.
Язык: Английский
Процитировано
0
Heliyon, Год журнала: 2024, Номер unknown, С. e26063 - e26063
Опубликована: Фев. 1, 2024
Accumulating evidence has highlighted a strong association between gut microbiota and the occurrence, development, prevention, treatment of atopic dermatitis (AD). The regulation microbial dysbiosis by oral traditional Chinese medicine (TCM) garnered significant attention. In AD, TCM formula Qingre-Qushi Recipe (QRQS) demonstrated clinical efficacy. However, both therapeutic mechanisms QRQS its impact on remain unclear. Thus, our study aimed to assess efficacy evaluate influence composition diversity in AD animal models. First, we investigated effect using two models: filaggrin-deficient mice (Flaky tail, ft/ft) MC903-induced AD-like mice. Subsequently, explored microbiota. Our results that ameliorated symptoms ft/ft It also reduced levels serum IgE pro-inflammatory cytokines, including IL-1β, IL-4, IL-5, IL-9, IL-13, IL-17A, TNF-α. Furthermore, remarkably regulated increasing Lactobacillaceae decreasing Bacteroidale. inflammatory factors peripheral showed close correlation with microbiota, as determined Spearman coefficient. Additionally, PICRUSt analysis revealed an enrichment ascorbate aldarate metabolism, fatty acid metabolism biosynthesis, propanoate group compared control group. Finally, identified liquiritin primary active ingredient ultra-high-performance liquid chromatography-high-resolution mass spectrometry (UPLC-HRMS). findings improved alleviated skin inflammation This suggests modulating may help elucidate anti-inflammation activation mechanism, highlighting new strategy targets intestinal flora prevent treat AD.
Язык: Английский
Процитировано
3
Advances in Skin & Wound Care, Год журнала: 2024, Номер 37(7), С. 346 - 352
Опубликована: Июнь 20, 2024
To review issues related to atopic dermatitis, including its classification, clinical presentation, potential triggers, and treatment options.
Язык: Английский
Процитировано
3
Dermatitis, Год журнала: 2023, Номер 35(3), С. 208 - 218
Опубликована: Июль 20, 2023
Abstract: This systematic review and meta-analysis aimed to explore the association between atopic dermatitis (AD) alopecia areata (AA). A comprehensive search was conducted in PubMed, Embase, Cochrane, Web of Science from inception each database November 10, 2022 for relevant studies. As there is a potential bilateral 2 diseases, we assessed prevalence/incidence AA patients with AD AA. total 29 studies involving 11,233,448 participants were included this analysis. exposure factor 23 studies, 7 both 1 study. The revealed that prevalence 11.2% (7.7%–15.1%) AA, 3.2% (95% confidence interval [CI]: 0.0%–11.5%) AD. incidence found vary age (P = 0.07). Based on significant when [odds ratio, OR, 4.537 CI: 2.409–8.544)]; based 10 also [OR 2.643 1.737–3.995)]. In conclusion, demonstrated 2-way providing clinical reference disease prevention control.
Язык: Английский
Процитировано
8
Dermatology and Therapy, Год журнала: 2022, Номер unknown
Опубликована: Сен. 19, 2022
Precision dermatology uses individualized dermatologic disease-directed targeted therapy (D
Язык: Английский
Процитировано
12
ACS Omega, Год журнала: 2024, Номер 9(16), С. 17931 - 17944
Опубликована: Апрель 10, 2024
The traditional prescription of Liangxue-Qushi-Zhiyang decoction (LQZ) has been demonstrated to be efficacious in treating atopic dermatitis (AD), a chronic inflammatory skin disorder marked by intense itching, redness, rashes, and thickening. Nevertheless, there an inadequate systematic exploration the potential targets, biological processes, pathways for AD treatment through LQZ. study objective was evaluate efficacy possible mechanism LQZ mice. In our study, we identified primary compounds LQZ, analyzed hub constructed network. Subsequently, predicted mechanisms were experimentally studied validated vivo, as determined network pharmacological analysis. A total 80 serum components ultra-performance liquid chromatography-electrospray ionization-tandem mass spectrometry (UPLC-ESI-MS/MS), among which 49 absorbed into bloodstream. Our results indicated that targets six putative key factors MAPK signaling pathway, play essential roles AD, namely, EGFR, p-MAPK1/3, p-MAPK14, IL-1β, IL-6, TNF-α. We observed spleen coefficient, scores, ear thickness all downregulated 2,4-dinitrochlorobenzene (DNCB)-induced mice after treatment. Histological analysis dorsal further revealed significantly decreased inflammation, epidermal thickness, mast cell numbers compared DNCB group. effectiveness reducing dermal damage mouse model AD. Furthermore, findings suggest downregulating pathway could therapeutic strategy
Язык: Английский
Процитировано
2
Biomedicine & Pharmacotherapy, Год журнала: 2024, Номер 176, С. 116911 - 116911
Опубликована: Июнь 11, 2024
Atopic dermatitis (AD) is a globally increasing chronic inflammatory skin disease with limited and potentially side-effect-prone treatment options. Monotropein the predominant iridoid glycoside in Morinda officinalis How roots, which has previously shown promise alleviating AD symptoms. This study aimed to systematically investigate pharmacological effects of monotropein on using 2, 4-dinitrochlorobenzene (DNCB)/Dermatophagoides farinae extract (DFE)-induced mice tumor necrosis factor (TNF)-α/interferon (IFN)-γ-stimulated keratinocytes. Oral administration demonstrated significant reduction phenotypes, including scaling, erythema, increased thickness AD-induced mice. Histological analysis revealed marked decrease immune cell infiltration lesions. Additionally, effectively downregulated markers, encompassing pro-inflammatory cytokines, T helper (Th)1 Th2 chemokines tissues. Notably, also led considerable serum immunoglobulin (Ig)E IgG2a levels. At mechanistic level, exerted its anti-inflammatory by suppressing phosphorylation Janus kinase / signal transducer activator transcription proteins both tissues TNF-α/IFN-γ-stimulated In conclusion, exhibited pronounced alleviation symptoms experimental models used. These findings underscore potential application as therapeutic agent context AD, providing scientific basis for further exploration development.
Язык: Английский
Процитировано
2
Frontiers in Allergy, Год журнала: 2024, Номер 5
Опубликована: Ноя. 14, 2024
Atopic dermatitis (AD) is a chronic inflammatory skin disorder that affects millions worldwide, presenting challenges in managing symptoms and quality of life. Current treatments include topical corticosteroids (TCS), but novel approaches, such as Janus kinase (JAK) inhibitors, show promise. Baricitinib, selective JAK1 JAK2 inhibitor, targets cytokines involved AD offers potential benefits beyond traditional therapies.
Язык: Английский
Процитировано
2